A Phase 4, Open-label, Randomized, Prospective, Interventional Post-authorization Efficacy and Safety Study of Mirabegron 50 mg and 25 mg for the Treatment of Overactive Bladder in Chinese Subjects
Latest Information Update: 31 Mar 2023
At a glance
- Drugs Mirabegron (Primary)
- Indications Overactive bladder
- Focus Therapeutic Use
- Sponsors Astellas Pharma China
- 14 Apr 2022 Status changed from active, no longer recruiting to completed.
- 24 Feb 2022 Planned End Date changed from 2 Jun 2022 to 31 Mar 2022.
- 24 Feb 2022 Planned primary completion date changed from 19 May 2022 to 31 Mar 2022.